Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.

Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.

Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

Abstract: A gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof is disclosed, and more specifically a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3 member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

Abstract: Provided is an Open ID authentication method using an identity selector, which can simplify the authentication of an open ID and reduce phishing and hacking risks by automatically performing an open ID-based login process without the need to manually input an open ID uniform resource locator (URL) to a login window.